PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
PSMA-PET
hormone sensitive prostate cancer
metastasis-directed therapy
oligorecurrent prostate cancer
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Mar 2023
29 Mar 2023
Historique:
received:
06
03
2023
revised:
27
03
2023
accepted:
28
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) is used to select recurrent prostate cancer (PCa) patients for metastases-directed therapy (MDT). We aimed to evaluate the oncologic outcomes of second-line PSMA-guided MDT in oligo-recurrent PCa patients. we performed a retrospective analysis of 113 recurrent PCa after previous radical prostatectomy and salvage therapies with oligorecurrent disease at PSMA-PET (≤3 lesions in N1/M1a-b) in three high-volume European centres. Patients underwent second-line salvage treatments: MDT targeted to PSMA (including surgery and/or radiotherapy), and the conventional approach (observation or Androgen Deprivation Therapy [ADT]). Patients were stratified according to treatments (MDT vs. conventional approach). Patients who underwent MDT were stratified according to stage in PSMA-PET (N1 vs. M1a-b). The primary outcome of the study was Progression-free survival (PFS). Secondary outcomes were Metastases-free survival (MFS) and Castration Resistant PCa free survival (CRPC-FS). Kaplan-Meier analyses assessed PFS, MFS and CRPC-FS. Multivariable Cox regression models identified predictors of progression and metastatic disease. Overall, 91 (80%) and 22 (20%) patients were treated with MDT and the conventional approach, respectively. The median follow-up after PSMA-PET was 31 months. Patients who underwent MDT had a similar PFS compared to the conventional approach (
Sections du résumé
BACKGROUND
BACKGROUND
Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) is used to select recurrent prostate cancer (PCa) patients for metastases-directed therapy (MDT). We aimed to evaluate the oncologic outcomes of second-line PSMA-guided MDT in oligo-recurrent PCa patients.
METHODS
METHODS
we performed a retrospective analysis of 113 recurrent PCa after previous radical prostatectomy and salvage therapies with oligorecurrent disease at PSMA-PET (≤3 lesions in N1/M1a-b) in three high-volume European centres. Patients underwent second-line salvage treatments: MDT targeted to PSMA (including surgery and/or radiotherapy), and the conventional approach (observation or Androgen Deprivation Therapy [ADT]). Patients were stratified according to treatments (MDT vs. conventional approach). Patients who underwent MDT were stratified according to stage in PSMA-PET (N1 vs. M1a-b). The primary outcome of the study was Progression-free survival (PFS). Secondary outcomes were Metastases-free survival (MFS) and Castration Resistant PCa free survival (CRPC-FS). Kaplan-Meier analyses assessed PFS, MFS and CRPC-FS. Multivariable Cox regression models identified predictors of progression and metastatic disease.
RESULTS
RESULTS
Overall, 91 (80%) and 22 (20%) patients were treated with MDT and the conventional approach, respectively. The median follow-up after PSMA-PET was 31 months. Patients who underwent MDT had a similar PFS compared to the conventional approach (
Identifiants
pubmed: 37046687
pii: cancers15072027
doi: 10.3390/cancers15072027
pmc: PMC10093227
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268
pubmed: 35217883
Int J Urol. 2019 Aug;26(8):804-811
pubmed: 31083784
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Eur Urol. 2021 Sep;80(3):374-382
pubmed: 33685838
Eur Urol Oncol. 2023 Feb;6(1):41-48
pubmed: 34933814
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
BMC Cancer. 2014 Sep 15;14:671
pubmed: 25223986
J Nucl Med. 2018 Mar;59(3):434-441
pubmed: 29242398
Minerva Urol Nefrol. 2020 Aug;72(4):464-473
pubmed: 31144486
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1622-1635
pubmed: 28536833
Cancers (Basel). 2023 Mar 10;15(6):
pubmed: 36980602
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):136-146
pubmed: 31492993
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
BMC Cancer. 2020 May 12;20(1):406
pubmed: 32398040
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
Eur Urol Oncol. 2022 Feb;5(1):44-51
pubmed: 34785189
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2100-2105
pubmed: 32006061
Eur Urol. 2020 Nov;78(5):661-669
pubmed: 32624288
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19
pubmed: 29905907
Eur Urol Focus. 2021 Mar;7(2):238-240
pubmed: 33386288
Cancers (Basel). 2022 Dec 30;15(1):
pubmed: 36612242
Front Oncol. 2023 Feb 07;13:1101221
pubmed: 36824128
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406542
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877